PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces New SensoLyte™ 520 Cathepsin S Assay Kit - AnaSpec has introduced the SensoLyte™ 520 Cathepsin S Assay Kit to its broad collection of long wavelength FRET protease assay kits
AnaSpec Introduces New SensoLyte™ 520 Cathepsin S Assay Kit

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2008/05/27 - AnaSpec has introduced the SensoLyte™ 520 Cathepsin S Assay Kit to its broad collection of long wavelength FRET protease assay kits.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Adding to a broad collection of long wavelength FRET protease assay kits, AnaSpec has introduced the SensoLyte™ 520 Cathepsin S Assay Kit.
The SensoLyte™ 520 Cathepsin S Activity Assay Kit is a homogeneous assay that can be used to detect the activity of Cathepsin S in biological samples or in purified enzyme preparations. A unique long wavelength 5-FAM/QXL™ 520 FRET peptide substrate is used in this kit. When active Cathepsin S cleaves this FRET substrate, it results in an increase of 5-FAM fluorescence, which can be monitored at Ex/Em = 490 nm/520 nm. The long wavelength fluorescence of 5-FAM is less interfered by the autofluorescence of cell components and test compounds.

Cathepsin S is a lysosomal cysteine proteinase of the papain family. It plays a major role in the degradation of the invariant peptide chain associated with the major histocompatibility complex and thus affects antigen presentation.1, 2 Since antigen presentation is the key to immune response, Cathepsin S has been validated as an immunomodulatory target.3, 4 Cathepsin S is also involved in several pathologies including atherosclerosis, cancer, obesity and their associated diseases.5-9

AnaSpec also provides the SensoLyte 440 Cathespsin S Activity Assay Kit. The substrate used in this kit releases the AMC (7-amino-4-methylcoumarin) fluorophore upon Cathepsin S cleavage. AMC has bright blue fluorescence that can be detected with excitation at 354 nm and emission at 442 nm.

About AnaSpec, Inc.
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry.

References:
1. Honey, K and AY. Rudensky, Nat. Rev. Immunol. 3, 472 (2003)
2. Hsieh, CS. et al, J. Immunol. 168, 2618 (2002)
3. Gupta, S. et al, Expert Opin. Ther. Targets 12, 291 (2008)
4. Thurmond, RL et al, Curr. Opin. Investi.g Drugs 6, 473 (2005)
5. Sukhova, GK. et al, J. Clin. Invest. 111, 897 (2003)
6. Taleb, S. et al, FASEB J. 19, 1540 (2005)
7. Liu, J. et al, Atherosclerosis 186, 411 (2006)
8. Taleb, S. et al, J. Clin. Endocrinol. Metab. 91, 1042 (2006)
9. Wang, B. et al, J. Biol. Chem. 281, 6020 (2006).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces New SensoLyte™ 520 Cathepsin S Assay Kit

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Ping Yang 
408-452-5055 ping[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)